tiprankstipranks
Nuvalent, Inc. Class A (NUVL)
NASDAQ:NUVL
US Market
Want to see NUVL full AI Analyst Report?

Nuvalent (NUVL) Stock Forecast & Price Target

205 Followers
See the Price Targets and Ratings of:

NUVL Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
6 Buy
11 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Nuvalent
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NUVL Stock 12 Month Forecast

Average Price Target

$131.30
▲(22.01% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Nuvalent in the last 3 months. The average price target is $131.30 with a high forecast of $172.00 and a low forecast of $116.00. The average price target represents a 22.01% change from the last price of $107.61.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"$75","124":"$124","173":"$173","99.5":"$99.5","148.5":"$148.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":172,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$172.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":131.29615384615386,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$131.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$116.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,99.5,124,148.5,173],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.01,99.08615384615385,105.16230769230769,111.23846153846154,117.3146153846154,123.39076923076922,129.46692307692308,135.5430769230769,141.61923076923077,147.69538461538463,153.77153846153846,159.84769230769228,165.92384615384617,{"y":172,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.01,95.95508875739645,98.9001775147929,101.84526627218935,104.79035502958581,107.73544378698226,110.6805325443787,113.62562130177515,116.5707100591716,119.51579881656806,122.4608875739645,125.40597633136096,128.35106508875742,{"y":131.29615384615386,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.01,94.77846153846154,96.54692307692308,98.31538461538462,100.08384615384615,101.85230769230769,103.62076923076924,105.38923076923078,107.15769230769232,108.92615384615385,110.69461538461539,112.46307692307693,114.23153846153846,{"y":116,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":77.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.58,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.59,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.29,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.64,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.04,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.01,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$172.00Average Price Target$131.30Lowest Price Target$116.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on NUVL
Barclays
Barclays
$152$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Equal Weight from Overweight at BarclaysNuvalent downgraded to Equal Weight from Overweight at Barclays
J.P. Morgan Analyst forecast on NUVL
J.P. Morgan
J.P. Morgan
$147$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Overweight at JPMorganNuvalent downgraded to Neutral from Overweight at JPMorgan
Piper Sandler Analyst forecast on NUVL
Piper Sandler
Piper Sandler
$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Overweight at Piper SandlerNuvalent downgraded to Neutral from Overweight at Piper Sandler
Cantor Fitzgerald Analyst forecast on NUVL
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Overweight at Cantor FitzgeraldNuvalent downgraded to Neutral from Overweight at Cantor Fitzgerald
Wedbush
$125$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Outperform at WedbushNuvalent downgraded to Neutral from Outperform at Wedbush
TD Cowen Analyst forecast on NUVL
TD Cowen
TD Cowen
$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent (NUVL) was downgraded to a Hold Rating at TD Cowen
LifeSci Capital Analyst forecast on NUVL
LifeSci Capital
LifeSci Capital
$142$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Market Perform from Outperform at LifeSci CapitalNuvalent downgraded to Market Perform from Outperform at LifeSci Capital
Truist Financial Analyst forecast on NUVL
Truist Financial
Truist Financial
Buy
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Nuvalent (NASDAQ: NUVL) and Viking Therapeutics (NASDAQ: VKTX)
H.C. Wainwright Analyst forecast on NUVL
H.C. Wainwright
H.C. Wainwright
$155$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Buy at H.C. WainwrightNuvalent downgraded to Neutral from Buy at H.C. Wainwright
Canaccord Genuity Analyst forecast on NUVL
Canaccord Genuity
Canaccord Genuity
Hold
Downgraded
06/09/26
Nuvalent downgraded to Hold from Buy at CanaccordNuvalent downgraded to Hold from Buy at Canaccord
Raymond James Analyst forecast on NUVL
Raymond James
Raymond James
Hold
Downgraded
06/09/26
Nuvalent downgraded to Market Perform from Outperform at Raymond JamesNuvalent downgraded to Market Perform from Outperform at Raymond James
Robert W. Baird Analyst forecast on NUVL
Robert W. Baird
Robert W. Baird
$158$122.85
Hold
14.16%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Outperform at BairdNuvalent downgraded to Neutral from Outperform at Baird
Wells Fargo
$116
Buy
7.80%
Upside
Assigned
06/08/26
Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), Lyell Immunopharma (NASDAQ: LYEL) and BioCardia (NASDAQ: BCDA)
Bernstein Analyst forecast on NUVL
Unknown Analyst
Bernstein
Not Ranked
Bernstein
$172
Buy
59.84%
Upside
Assigned
06/04/26
Bernstein Releases a Buy Rating on Nuvalent (NUVL)
Goldman Sachs Analyst forecast on NUVL
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$139$142
Buy
31.96%
Upside
Reiterated
06/01/26
Goldman Sachs Sticks to Its Buy Rating for Nuvalent (NUVL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on NUVL
Barclays
Barclays
$152$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Equal Weight from Overweight at BarclaysNuvalent downgraded to Equal Weight from Overweight at Barclays
J.P. Morgan Analyst forecast on NUVL
J.P. Morgan
J.P. Morgan
$147$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Overweight at JPMorganNuvalent downgraded to Neutral from Overweight at JPMorgan
Piper Sandler Analyst forecast on NUVL
Piper Sandler
Piper Sandler
$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Overweight at Piper SandlerNuvalent downgraded to Neutral from Overweight at Piper Sandler
Cantor Fitzgerald Analyst forecast on NUVL
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Overweight at Cantor FitzgeraldNuvalent downgraded to Neutral from Overweight at Cantor Fitzgerald
Wedbush
$125$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Outperform at WedbushNuvalent downgraded to Neutral from Outperform at Wedbush
TD Cowen Analyst forecast on NUVL
TD Cowen
TD Cowen
$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent (NUVL) was downgraded to a Hold Rating at TD Cowen
LifeSci Capital Analyst forecast on NUVL
LifeSci Capital
LifeSci Capital
$142$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Market Perform from Outperform at LifeSci CapitalNuvalent downgraded to Market Perform from Outperform at LifeSci Capital
Truist Financial Analyst forecast on NUVL
Truist Financial
Truist Financial
Buy
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Nuvalent (NASDAQ: NUVL) and Viking Therapeutics (NASDAQ: VKTX)
H.C. Wainwright Analyst forecast on NUVL
H.C. Wainwright
H.C. Wainwright
$155$124
Hold
15.23%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Buy at H.C. WainwrightNuvalent downgraded to Neutral from Buy at H.C. Wainwright
Canaccord Genuity Analyst forecast on NUVL
Canaccord Genuity
Canaccord Genuity
Hold
Downgraded
06/09/26
Nuvalent downgraded to Hold from Buy at CanaccordNuvalent downgraded to Hold from Buy at Canaccord
Raymond James Analyst forecast on NUVL
Raymond James
Raymond James
Hold
Downgraded
06/09/26
Nuvalent downgraded to Market Perform from Outperform at Raymond JamesNuvalent downgraded to Market Perform from Outperform at Raymond James
Robert W. Baird Analyst forecast on NUVL
Robert W. Baird
Robert W. Baird
$158$122.85
Hold
14.16%
Upside
Downgraded
06/09/26
Nuvalent downgraded to Neutral from Outperform at BairdNuvalent downgraded to Neutral from Outperform at Baird
Wells Fargo
$116
Buy
7.80%
Upside
Assigned
06/08/26
Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), Lyell Immunopharma (NASDAQ: LYEL) and BioCardia (NASDAQ: BCDA)
Bernstein Analyst forecast on NUVL
Unknown Analyst
Bernstein
Not Ranked
Bernstein
$172
Buy
59.84%
Upside
Assigned
06/04/26
Bernstein Releases a Buy Rating on Nuvalent (NUVL)
Goldman Sachs Analyst forecast on NUVL
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$139$142
Buy
31.96%
Upside
Reiterated
06/01/26
Goldman Sachs Sticks to Its Buy Rating for Nuvalent (NUVL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nuvalent

3 Months
Bradley CaninoGuggenheim
Success Rate
7/12 ratings generated profit
58%
Average Return
+12.08%
Copying Bradley Canino's trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +12.08% per trade.
1 Year
Andrew BerensLeerink Partners
Success Rate
8/11 ratings generated profit
73%
Average Return
+10.21%
Copying Andrew Berens's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +10.21% per trade.
2 Years
Andrew BerensLeerink Partners
Success Rate
8/11 ratings generated profit
73%
Average Return
+19.55%
Copying Andrew Berens's trades and holding each position for 2 Years would result in 72.73% of your transactions generating a profit, with an average return of +19.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NUVL Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
4
4
3
3
6
Buy
19
21
24
28
28
Hold
0
0
0
0
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
25
27
31
47
In the current month, NUVL has received 34 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. NUVL average Analyst price target in the past 3 months is 131.30.
Each month's total comprises the sum of three months' worth of ratings.

NUVL Financial Forecast

NUVL Earnings Forecast

Next quarter’s earnings estimate for NUVL is -$1.41 with a range of -$1.56 to -$1.22. The previous quarter’s EPS was -$1.39. NUVL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.
Next quarter’s earnings estimate for NUVL is -$1.41 with a range of -$1.56 to -$1.22. The previous quarter’s EPS was -$1.39. NUVL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.
No data currently available

NUVL Sales Forecast

Next quarter’s sales forecast for NUVL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NUVL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.
Next quarter’s sales forecast for NUVL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NUVL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.

NUVL Stock Forecast FAQ

What is NUVL’s average 12-month price target, according to analysts?
Based on analyst ratings, Nuvalent, Inc. Class A’s 12-month average price target is 131.30.
    What is NUVL’s upside potential, based on the analysts’ average price target?
    Nuvalent, Inc. Class A has 22.01% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NUVL a Buy, Sell or Hold?
          Nuvalent, Inc. Class A has a consensus rating of Moderate Buy which is based on 6 buy ratings, 11 hold ratings and 0 sell ratings.
            What is Nuvalent, Inc. Class A’s price target?
            The average price target for Nuvalent, Inc. Class A is 131.30. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $172.00 ,the lowest forecast is $116.00. The average price target represents 22.01% Increase from the current price of $107.61.
              What do analysts say about Nuvalent, Inc. Class A?
              Nuvalent, Inc. Class A’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of NUVL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.